scispace - formally typeset
F

Friedemann Weber

Researcher at University of Giessen

Publications -  180
Citations -  16428

Friedemann Weber is an academic researcher from University of Giessen. The author has contributed to research in topics: Virus & Interferon. The author has an hindex of 62, co-authored 166 publications receiving 14626 citations. Previous affiliations of Friedemann Weber include University Medical Center Freiburg & University of Marburg.

Papers
More filters
Journal ArticleDOI

RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5' Phosphates

TL;DR: It is shown that influenza A virus infection does not generate dsRNA and that RIG-I is activated by viral genomic single-stranded RNA (ssRNA) bearing 5′-phosphates, and suggested that its ability to sense 5'-phosphorylated RNA evolved in the innate immune system as a means of discriminating between self and nonself.
Journal ArticleDOI

Double-Stranded RNA Is Produced by Positive-Strand RNA Viruses and DNA Viruses but Not in Detectable Amounts by Negative-Strand RNA Viruses

TL;DR: Investigation of the presence and localization of ds RNA in cells infected with a range of viruses, employing a dsRNA-specific antibody for immunofluorescence analysis revealed that significant amounts ofdsRNA can be detected for viruses with a genome consisting of positive-strand RNA, dsRNAs, or DNA; Surprisingly, however, no DsRNA signals were detected for negative-stranded RNA viruses.
Journal ArticleDOI

The interferon response circuit: Induction and suppression by pathogenic viruses

TL;DR: The current view on the balancing act between virus-induced IFN responses and the viral counterplayers is discussed.
Journal ArticleDOI

Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments]

TL;DR: There is a high proportion of patients with circulating tumor cells under steady-state conditions, and in addition a substantial risk of concomitant tumor cell recruitment upon mobilization of PBPCs, particularly in stage IV breast cancer patients with bone marrow infiltration.